Otros idiomas ALX Oncology Holdings Inc.

Acciones

ALXO

US00166B1052

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
16,86 ^USD	-0,06 %		+8,08 %	+13,23 %

18/04	Un iniciado de Alx Oncology Holdings vendió acciones por valor de 710.195 dólares, según un reciente registro de la SEC	MT
10/04	ALX Oncology informa de datos positivos del ensayo en curso de fase 1/2 de evorpacept	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting	24/04
Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	18/04
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	10/04
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)	09/04
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	09/04
ALX Oncology : Corporate Presentation	11/03
North American Morning Briefing : Stock Futures -2-	11/03
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	07/03
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	05/03
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	05/03
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
ALX Oncology Holdings Inc. and ALX Oncology Inc. Enter into the Third Amendment to Loan and Security Agreement	26/12
North American Morning Briefing : Investors Await -2-	11/12
Top Midday Gainers	08/12
Sector Update: Health Care Stocks Advance Premarket Tuesday	14/11
ALX Oncology Reports Q3 Results With 'Sufficient' Funds to Finance Operations Into Early 2026	13/11
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours	13/11
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas ALX Oncology Holdings Inc.

Acciones

ALXO

US00166B1052

Otros idiomas

Filtros